Rezafungin Dosage and Clinical Indications
Rezafungin is approved for treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options, administered as a 400 mg IV loading dose followed by 200 mg IV once weekly for 2-4 weeks total. 1
FDA-Approved Indication
Rezafungin (Rezzayo®) is specifically indicated for:
- Candidemia and invasive candidiasis in adults with limited or no alternative treatment options 1
- This represents the fourth echinocandin approved in this class, joining caspofungin, micafungin, and anidulafungin 2
Dosing Regimen
Standard Dosing
- Loading dose: 400 mg IV on Day 1 of Week 1 1
- Maintenance dose: 200 mg IV once weekly 1
- Duration: 2-4 weeks total (2-4 doses) 1
- Administration: IV infusion over 1 hour 1
This once-weekly dosing represents a significant departure from first-generation echinocandins (caspofungin, micafungin, anidulafungin), which all require daily administration 3. The extended dosing interval is enabled by rezafungin's prolonged half-life of approximately 152 hours 1.
Special Populations
No dose adjustments are required for: 1
- Age (range 20-89 years studied)
- Sex
- Race
- Weight (34-154.5 kg range)
- Hepatic impairment (Child-Pugh Class B or C)
- Renal impairment (creatinine clearance 9.3 mL/min to >120 mL/min)
- Patients on hemodialysis
Clinical Efficacy Evidence
Pivotal Trial Data
The ReSTORE phase 3 trial demonstrated non-inferiority to caspofungin: 4
- Day 14 global cure: 59% (rezafungin) vs 61% (caspofungin) - meeting the EMA primary endpoint 4
- Day 30 all-cause mortality: 24% (rezafungin) vs 21% (caspofungin) - meeting the FDA primary endpoint 4
- Median time to negative blood culture: 19.5 hours (rezafungin) vs 22.8 hours (caspofungin) 5
Pooled analysis of STRIVE (phase 2) and ReSTORE trials showed: 6
- Day 5 mycological eradication: 73% (rezafungin) vs 65% (caspofungin) 6
- This suggests potential early treatment benefit, likely reflecting the front-loaded dosing regimen 6
ICU Population
In critically ill patients (pooled ICU subgroup analysis): 7
- Day 5 mycological eradication: 78.3% (rezafungin) vs 59.7% (caspofungin) 7
- Median time to negative blood culture: 18 hours (rezafungin) vs 38 hours (caspofungin) - statistically significant difference (P=0.001) 7
- Approximately 30% of patients had impaired renal function and/or APACHE II score ≥20 at baseline 7
Spectrum of Activity
Candida Species Coverage
Rezafungin demonstrates activity against: 1
- FDA-approved indications with clinical data: C. albicans, C. glabrata, C. parapsilosis, C. tropicalis 1
- In vitro activity (≥90% susceptible): C. krusei, C. auris, C. dubliniensis, C. guilliermondii, C. lusitaniae, and others 1
Resistance Considerations
Important caveat: Rezafungin exhibits cross-resistance with other echinocandins for FKS mutations 1. Reduced susceptibility arises from mutations in FKS1/FKS2 genes affecting "hot spot" regions 1. However, the once-weekly high-dose regimen may theoretically reduce local resistance promotion compared to daily echinocandins 8.
Clinical Positioning
When to Consider Rezafungin
Primary scenarios for rezafungin use: 9, 10
- Patients requiring outpatient parenteral antifungal therapy (OPAT)
- Azole-resistant Candida species where oral step-down is not feasible
- Patients with significant drug-drug interactions precluding azole use
- Facilitation of earlier hospital discharge
- Patient preference for less frequent dosing
Advantages over daily echinocandins: 9, 10
- Reduces catheter-related complications (estimated 157 catheter-days saved per 6 patients in one case series) 9
- Front-loaded dosing may achieve faster mycological clearance 6, 7
- Improved convenience and quality of life for outpatient treatment 9, 10
Comparison to Guideline-Recommended Echinocandins
Current IDSA guidelines (2016) recommend for candidemia: 3
- Caspofungin: 70 mg loading dose, then 50 mg daily
- Micafungin: 100 mg daily
- Anidulafungin: 200 mg loading dose, then 100 mg daily
Rezafungin is NOT interchangeable with conventional echinocandins due to its extremely long half-life and different dosing paradigm 11. It should be considered as a distinct therapeutic option rather than a direct substitute 11.
Safety Profile
Common Adverse Events
Treatment-emergent adverse events (≥5% incidence): 4
- Pyrexia
- Hypokalaemia
- Pneumonia
- Septic shock
- Anaemia
- Diarrhoea
Overall safety: 91% of rezafungin patients experienced at least one treatment-emergent adverse event vs 85% with caspofungin, with similar rates of serious adverse events (56% vs 53%) 4.
Important Safety Signal
Neurotoxicity in animal studies: 1, 12
- Tremors, axonal degeneration, and demyelination observed in non-human primates at exposures ≥6 times clinical exposure 1
- Some findings persisted through 52-week reversibility periods 1
- However, clinical trials showed no concerning neurotoxicity trends in humans 12
- Safety profile in completed studies was similar to other FDA-approved echinocandins 12
Drug Interactions
Minimal drug-drug interactions: 1
- No clinically significant effects on CYP450 substrates (CYP1A2, CYP2C8, CYP3A)
- No significant effects on drug transporters (P-gp, OATP, BCRP, OCT, MATE)
- No dose adjustments needed for commonly co-administered drugs (tacrolimus, cyclosporine, mycophenolate, ibrutinib, venetoclax) 1
This contrasts favorably with azoles, which have extensive CYP3A4 interactions requiring careful management with proteasome inhibitors, tyrosine kinase inhibitors, and vinca alkaloids 2.
Limitations and Caveats
Excluded Populations
Rezafungin trials excluded patients with: 1
- CNS candidiasis (meningitis, endophthalmitis, chorioretinitis)
- Endocarditis or myocarditis
- Chronic disseminated candidiasis
- Osteomyelitis or septic arthritis in prosthetic joints
- Ascending urinary tract candidiasis with obstruction
For these deep-seated infections, follow IDSA guidelines recommending lipid formulation amphotericin B or echinocandins for several weeks, followed by fluconazole 3.
Aspergillosis
Rezafungin is NOT approved for invasive aspergillosis 11. While one case report describes combination use with voriconazole for azole-refractory pulmonary aspergillosis 9, this represents off-label use without supporting clinical trial data. The 2025 ATS guidelines explicitly state rezafungin has not been studied in human IPA trials and cannot be considered interchangeable with conventional echinocandins for this indication 11.
Practical Implementation
Transition to Outpatient Therapy
Rezafungin enables earlier OPAT transition: 9, 10
- After ≥3 days of therapy and clinical stability, patients can continue weekly infusions as outpatients
- Reduces need for central venous catheters compared to daily echinocandin regimens
- Particularly valuable when azole step-down is contraindicated due to resistance or drug interactions
Treatment Duration
Standard duration: 2 weeks after documented clearance of Candida from bloodstream and resolution of symptoms 3, 1. This translates to:
- Minimum 2 doses (if clearance occurs rapidly)
- Maximum 4 doses for most uncomplicated cases
- Extended therapy for deep-seated infections per IDSA guidelines 3